Research programme: hearing and balance loss gene therapy - GenVec/Novartis

Drug Profile

Research programme: hearing and balance loss gene therapy - GenVec/Novartis

Alternative Names: Atonal gene therapy - GenVec/Novartis; Hearing loss gene therapy - GenVec/Novartis; math1 gene therapy - GenVec/Novartis; TherAtoH atonal therapy - GenVec/Novartis

Latest Information Update: 20 May 2014

Price : $50

At a glance

  • Originator Baylor College of Medicine
  • Developer GenVec; Novartis
  • Class Gene therapies
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ear disorders

Most Recent Events

  • 01 May 2014 Novartis plans a phase I/II trial for Hearing loss in USA (NCT02132130)
  • 09 Aug 2011 Preclinical development is ongoing in USA
  • 20 Jan 2010 GenVec's hearing loss and balance disorders program licensed to Novartis worldwide for the treatment of Ear disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top